Anti-CD44 and EGFR Dual-Targeted Solid Lipid Nanoparticles for Delivery of Doxorubicin to Triple-Negative Breast Cancer Cell Line: Preparation, Statistical Optimization, and <i>In Vitro</i> Characterization

<div>A: doxorubicin encapsulated in solid lipid nanoparticles. B: EGFR is significantly expressed in TNBC and has an essential role in tumor angiogenesis. C: DEXA_LHON, as a ligand affecting the glucocorticoid receptor, facilitates the transport of the nanoparticle into the nucleus. D: CD44 is the most important marker of cancer stem cells.</div>

BioMed Research International

fig1

Figure 1

Figure 1: Anti-CD44 and EGFR Dual-Targeted Solid Lipid Nanoparticles for Delivery of Doxorubicin to Triple-Negative Breast Cancer Cell Line: Preparation, Statistical Optimization, and <i>In Vitro</i> Characterization 

Figure 1 | Anti-CD44 and EGFR Dual-Targeted Solid Lipid Nanoparticles for Delivery of Doxorubicin to Triple-Negative Breast Cancer Cell Line: Preparation, Statistical Optimization, and In Vitro Characterization 